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Objectives This study sought to compare all-cause mortality in patients with Fidelis leads (Medtronic, Minneapolis, Minne-
sota) to those with a nonadvisory lead.
Background Although Fidelis leads are prone to fracture, and rare deaths due to lead failure have been reported, it is unclear
whether the presence of a Fidelis lead is associated with increased mortality. This study compares all-cause
mortality in a large cohort of patients with Fidelis and Quattro implantable cardioverter-defibrillator (ICD) leads.
Methods All patients with Fidelis (Medtronic models 6931, 6948, and 6949) and Quattro (Medtronic model 6947) leads fol-
lowed at 3 tertiary care centers were identified from the medical records (implant dates: November 19, 2001, to De-
cember 23, 2008). Clinical and device-specific data were collected into a common database. Deaths were identified
from medical records and the Social Security Death Index. Survival was estimated using the Kaplan-Meier method.
Results A total of 2,671 patients (1,030 Fidelis and 1,641 Quattro) were identified. There were 398 deaths: 147 in the
Fidelis group (mean follow-up: 34.4 months) and 251 in the Quattro group (mean follow-up: 39.9 months). No
deaths were associated with 85 Fidelis and 23 Quattro failures. At 4 years, survival was diminished in patients
with Fidelis compared with Quattro leads (80.7% vs. 83.9%, p  0.025). After adjustment for factors associated
with mortality, survival was similar between groups. One hundred percent pacing was not associated with mor-
tality. Elective removal of nonfailed leads was performed in 5.1% of Fidelis and 0.9% of Quattro patients.
Conclusions In a conservatively managed cohort, in whom observation was predominantly utilized, adjusted survival is similar
between patients with Fidelis and Quattro ICD leads. (J Am Coll Cardiol 2011;58:278–83) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.027Implantable cardioverter-defibrillators (ICDs) have consis-
tently been shown to reduce mortality from sudden death in
high-risk patients (1–5). Appropriate system function re-
quires an intact lead to sense cardiac signals and deliver
therapy. The Sprint Fidelis (models 6930, 6931, 6948, and
6949) high-voltage ICD lead (Medtronic, Minneapolis,
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2011, accepted March 15, 2011.Minnesota) is predisposed to premature failure (6–10), and
death due to lead failure has been reported (11–13). In
addition, recent studies have demonstrated that the risk of
Fidelis failure increases over time (6,14,15), with greater
failure rates reported by independent centers than by the
manufacturer. Currently, an estimated 143,000 patients in
the United States have a Fidelis lead implanted (16).
See page 284
Whether patents with implanted Fidelis leads have an in-
creased mortality is not known. We therefore pooled data from
3 large centers to determine whether patients with a Fidelis
lead in service are at increased risk of death compared with
similar patients with nonadvisory leads (Quattro, Medtronic),
and sought to determine optimal follow-up and management.
Methods
Study design. All patients with Medtronic Sprint Fidelis
(model numbers 6931, 6948, and 6949) and Medtronic
t
w
s
t
l
Q
3
m
O
t
w
U
F
0
w
Q
f
d
u
p
d
w
c
279JACC Vol. 58, No. 3, 2011 Morrison et al.
July 12, 2011:278–83 Impact of Sprint Fidelis Lead on Patient MortalityQuattro Secure (model number 6947) ICD leads followed
at Minneapolis Heart Institute (Minneapolis, Minnesota),
Beth Israel Deaconess Medical Center (Boston, Massachu-
setts), and Mayo Clinic (Rochester, Minnesota) that were
implanted between November 19, 2001, and December 23,
2008, were included in the study. This study was approved
by the institutional review board at each of the 3 partici-
pating institutions. Data regarding ICD lead implantation
and follow-up were collected prospectively at each center as
part of a local ICD database. Investigators from each site
formed a committee that identified clinical variables of
interest, which were given standardized definitions and then
merged to create a single database for the purpose of this
study. Study design, data collection and analysis, and
manuscript preparation were performed and funded by the
investigators.
All study leads were implanted by experienced cardiolo-
gists specializing in electrophysiology at 1 of the participat-
ing institutions. Lead placement was done via a left- or
right-sided cephalic cutdown, axillary, or subclavian vein
using standard introducer techniques. Leads were posi-
tioned in the right ventricular apex or ventricular septum.
Defibrillation safety margins and pacing threshold and
sensing measurements were obtained according to each
participating center’s protocol. Patients were followed every
3 to 4 months at clinic visits or remotely if appropriate.
Definitions. A lead was considered implanted after it was
ested, connected to the ICD pulse generator, and the incision
as closed. A lead failure was defined as a lead removed from
ervice due to an inability to meet its performance specifica-
ions or otherwise perform as intended (17). A lead failed if:
1) it exhibited abnormal impedance; 2) it exhibited electrical
noise as manifested by nonphysiological signals on the
electrogram or by pulse generator diagnostic data suggesting
rapid oversensing, for example, nonphysiological short in-
tervals and/or recurrent nonsustained ventricular tachycar-
dia with intervals usually 220 ms; or 3) it could not sense
R waves and/or provide effective electrical therapy due to an
apparent structural defect such as a conductor fracture or
insulation breach. Functional abnormalities, including exit
block and physiological oversensing in the presence of an
electrically intact lead, were not considered failures. Lead
displacement was not a lead failure unless a fixation mech-
anism defect was identified. Leads removed from service
were classified in accordance with the recommendations of
the Heart Rhythm Society (17).
Patient deaths were identified from local medical records
and from the Social Security Death Index (18). Appropriate
and inappropriate device therapies were determined at the
time of device interrogation by review of stored electro-
grams. A group of 100%-paced patients was defined as the
presence of complete heart block in the absence of a stable
escape rhythm or 100% pacing in patients not receiving
cardiac resynchronization therapy (CRT).
Statistical analysis. Continuous variables are presented as
a mean  SD, and discrete variables are summarized using egroup percentages. Comparisons
between lead types of patient
characteristics were tested using
the Pearson chi-square test for
continuous variables and the Stu-
dent 2-sample t test for discrete
variables. The relationship be-
tween patient demographics and
device characteristics with mor-
tality was analyzed with a univar-
iate analysis using Cox proportional hazards models. Uti-
lizing the same variables, a multivariate Cox proportional
hazard model was selected using the stepwise selection
technique. Unadjusted patient survival was estimated utiliz-
ing the Kaplan-Meier method. An adjusted comparison of
mortality between Fidelis and Quattro leads was performed
using the variables identified from the multivariate Cox
proportional hazard model. With our study population and
an alpha of 0.05, we had 80% power to detect a hazard ratio
of 1.38 in the multivariable model.
Results
A total of 2,671 patients (1,030 Fidelis and 1,641 Quattro)
were included. Baseline patient characteristics are shown in
Table 1. Patients with Fidelis leads were more likely to be
female and have resynchronization systems, a primary pre-
vention indication, and dilated cardiomyopathy. Patients
with Quattro leads were more likely to be male and have a
secondary prevention indication, previous bypass surgery,
ischemic cardiomyopathy, atrial fibrillation, and diabetes
mellitus. Fidelis leads in service were model 6949 (n 
1,007, 97.8%), model 6948 (n  2, 0.2%), and model 6931
(n  21, 2%). Elective removal from service of nonfailed
eads was performed in 53 (5.1%) of Fidelis and 15 (0.9%) of
uattro patients. Average follow-up was 34.4 months (range
.1 to 65.6 months) and 39.9 months (range 3.0 to 95.2
onths) for the Fidelis and Quattro patients, respectively.
utcomes. During follow-up, 398 patients died: 147 in
he Fidelis group and 251 in the Quattro group. No deaths
ere associated with 85 Fidelis and 23 Quattro lead failures.
nadjusted patient survival (Fig. 1) was diminished in the
idelis group as compared with the Quattro group (p 
.025). Patient survival at 48 months was 80.7% in patients
ith Fidelis leads compared with 83.9% in those with
uattro leads.
Inappropriate shocks were seen in 38 of 85 (45%) Fidelis
ailures. In addition to inappropriate shocks, 1 pacemaker-
ependent patient presented with presyncope and ventric-
lar asystole requiring emergent placement of a temporary
acemaker. Another patient receiving CRT showed evi-
ence of failure to pace on interrogation but did not present
ith a clinical event. Extraction of a failed lead was
omplicated by superior vena cava perforation requiring
Abbreviations
and Acronyms
CI  confidence interval
CRT  cardiac
resynchronization therapy
HR  hazard ratio
ICD  implantable
cardioverter-defibrillatormergent cardiac surgery in 1 patient.
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Quattro leads. Lead survival at 48 months was 87.0% and
98.7% (p  0.0001) in Fidelis and Quattro leads, respectively.
Univariate predictors of mortality. In univariate analysis,
Fidelis leads were associated with increased mortality (haz-
ard ratio [HR]: 1.28, 95% confidence interval [CI]: 1.03 to
1.60). Other device and patient factors associated with
increased mortality in univariate analysis were the presence
of an atrial lead, heart failure, CRT, increasing age, male
sex, ischemic cardiomyopathy, previous coronary artery
bypass grafting, history of stroke, history of peripheral
arterial disease, severe valvular disease, atrial fibrillation,
diabetes, increasing creatinine, dialysis, chronic obstructive
pulmonary disease, and pulmonary hypertension (Table 2).
Conversely, pulse generator changes, hypertrophic cardio-
myopathy, and increasing ejection fraction were associated
with decreased mortality.
Multivariate predictors of mortality. Secondary preven-
Patient CharacteristicsTable 1 Patient Characteristics
Variable
Fidelis Leads
(n  1,030)
Quattro Leads
(n  1,641) p Value
Indication of ICD 0.001
Primary 804 (78%) 1,185 (73%)
Secondary 221 (22%) 449 (27%)
Atrial lead 738 (72%) 1,194 (73%) 0.53
Heart failure 675 (67%) 1,060 (65%) 0.19
CRT device 399 (39%) 439 (27%) 0.001
Number of generator replacements 0.1 0.3 0.3 0.6 0.001
Age, yrs 63.8 15.4 65.0 14.0 0.05
Male 773 (75%) 1,291 (79%) 0.030
Underlying cardiac disease 0.001
Ischemic cardiomyopathy 537 (52%) 986 (60%)
Dilated cardiomyopathy 287 (28%) 371 (23%)
Hypertrophic cardiomyopathy 56 (5%) 93 (6%)
Channelopathy 12 (1%) 13 (1%)
Other 138 (13%) 178 (11%)
Coronary artery bypass surgery 325 (32%) 627 (38%) 0.001
Valve surgery 211 (21%) 361 (22%) 0.55
History of stroke 75 (7%) 141 (9%) 0.24
History of peripheral arterial
disease
87 (9%) 155 (9%) 0.40
Ejection fraction 31.1 14.6 31.5 14.8 0.47
Severe valvular heart disease 103 (11%) 136 (9%) 0.10
Atrial fibrillation 345 (34%) 644 (39%) 0.005
Diabetes 315 (31%) 581 (35%) 0.014
Creatinine 1.2 0.5 1.3 0.7 0.05
Chronic dialysis 16 (2%) 42 (3%) 0.09
Chronic obstructive pulmonary
disease
130 (13%) 227 (14%) 0.41
Pulmonary hypertension 76 (9%) 130 (9%) 0.89
100% paced 155 (18%) 270 (21%) 0.15
Appropriate shocks 205 (20%) 336 (20%) 0.72
Inappropriate shocks 201 (20%) 224 (14%) 0.001
Elective lead removal 53 (5%) 15 (1%) 0.001
Death 147 (14%) 251 (15%) 0.46
CRT  cardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator.tion indication, the presence of an atrial lead, heart failure,increasing age, history of peripheral artery disease, atrial
fibrillation, chronic dialysis, and chronic obstructive pulmo-
nary disease were independent predictors of mortality in a
multivariate model (Table 3). Increased numbers of pulse
generator replacements and increasing ejection fraction were
associated with decreased mortality in the multivariate
model. After adjustment for factors associated with mortal-
ity in the multivariate model, the presence of a Fidelis ICD
lead was not significantly associated with increased mortal-
ity (HR: 1.06, 95% CI: 0.84 to 1.33).
100% pacing. The presence of 100% pacing was not
associated with mortality in either the univariate (HR:
1.118, 95% CI: 0.86 to 1.46) or in the multivariate analyses.
Discussion
Implantable defibrillators perform critical lifesaving func-
tions (1–5). Whether a defibrillator lead at increased risk of
failure adversely impacts mortality depends on the nature
of the malfunction, the risk of death, and the ability of
surveillance techniques to identify malfunction prior to a
lethal event. We pooled raw data from 3 large tertiary
centers and found no increased risk of mortality due to the
presence of an active Fidelis advisory lead, as compared with
a similar cohort treated with a nonadvisory (Quattro) lead,
after adjusting for other factors. No patient deaths were as-
sociated with lead failure, and 100% pacing was not asso-
ciated with increased mortality. Importantly, a conservative
follow-up strategy was adopted, with elective removal from
service of nonfailed leads in only 53 (5.1%) of Fidelis and 15
(0.9%) of Quattro patients, with 36% (n  19) of elective
Fidelis removals performed in 100%-paced patients.
Mortality. Failure of a Fidelis ICD lead carries the poten-
tial risk of a fatal complication, and over 13 lead-related
Figure 1 Unadjusted Kaplan-Meier Patient
Survival Comparison by Lead Type
In an unadjusted Kaplan-Meier analysis, patients with active Fidelis implantable
cardioverter-defibrillator (ICD) leads have diminished survival at 48 months
compared with those with Quattro ICD leads (80.7% vs. 83.9%).
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Fidelis lead failure may lead to a fatal outcome: 1) fracture
of the pace-sense portion of the lead in a pacemaker-
dependent patient may lead to failure to pace (12);
2) fracture of the pace-sense portion of the lead can result in
oversensing and potentially fatal inappropriate shocks (11);
and 3) fracture of the high-voltage portion of the lead may
impair appropriate shock delivery.
Several factors likely account for the lack of increased
mortality seen in our study. All participating centers utilize
regular remote monitoring and thereby may identify lead
failures early, minimizing the risk for an adverse event.
Fracture of a pace-sense lead commonly presents with
intermittent, transient oversensing of rapid nonphysiologi-
cal make-break potentials, leading to inappropriate shock
(19). A downloadable algorithm identifies these potentials,
generates immediate audible and Internet-based alerts, and
increases the number of intervals needed to detect ventric-
ular arrhythmias, minimizing the risk of inappropriate
detection of ventricular tachycardia (20). Since the sense
amplifier in ICDs is continuously on to screen for ventric-
ular arrhythmias, this surveillance in conjunction with
Univariate Predictors of MortalityTable 2 Univariate Predictors of Mortality
Hazard Ratio (95% CI) p Value
Lead type (Fidelis vs. Quattro) 1.284 (1.03–1.60) 0.025
Indication (secondary vs. primary) 0.891 (0.71–1.12) 0.316
Atrial lead 1.428 (1.12–1.82) 0.0042
Heart failure 2.604 (2.02–3.36) 0.0001
CRT device 1.511 (1.23–1.86) 0.0001
Number of generator replacements
(per 1-PG increase)
0.379 (0.30–0.49) 0.0001
Age (per 1-yr increase) 1.05 (1.04–1.06) 0.0001
Male 1.391 (1.07–1.82) 0.0155
Ischemic cardiomyopathy 1.588 (1.28–1.97) 0.0001
Dilated cardiomyopathy 0.857 (0.67–1.10) 0.2228
Hypertrophic cardiomyopathy 0.279 (0.13–0.59) 0.0008
Channelopathy 0.965 (0.31–3.01) 0.9513
Other cardiac disease 0.651 (0.45–0.94) 0.0237
Coronary artery bypass surgery 1.536 (1.26–1.87) 0.0001
Valve surgery 1.205 (0.96–1.52) 0.1113
History of stroke 1.601 (1.19–2.15) 0.0019
History of peripheral arterial disease 2.126 (1.65–2.74) 0.0001
Ejection fraction (per 1% increase) 0.974 (0.966–0.98) 0.0001
Severe valvular heart disease 2.297 (1.76–3.0) 0.0001
Atrial fibrillation 1.954 (1.60–2.38) 0.0001
Diabetes 1.673 (1.37–2.04) 0.0001
Creatinine (per 1-mg/dl increase) 1.603 (1.50–1.72) 0.0001
Chronic dialysis 3.963 (2.68–5.86) 0.0001
Chronic obstructive pulmonary disease 1.872 (1.48–2.37) 0.0001
Pulmonary hypertension 1.482 (1.08–2.03) 0.0145
100% paced 1.118 (0.86–1.46) 0.4079
Appropriate shocks 1.017 (0.81–1.28) 0.8841
Inappropriate shocks 0.961 (0.74–1.24) 0.7599
Elective lead removal 0.989 (0.51–1.92) 0.9746
CI  confidence interval; PG  pulse generator; other abbreviations as in Table 1.aggressive use of Internet-based monitoring at participatingcenters may have prevented fatal events. Consequently,
bradycardic sudden death—which would require output
failure in the absence of significant nonphysiological
noise—appears to be an uncommon manifestation of this
mode of lead failure. Nonetheless, given the continuous
lifesaving nature of appropriate lead function in patients
who are otherwise asystolic (as opposed to an only inter-
mittent critical lead function during the time of arrhythmia
in other patients), a more aggressive approach towards lead
replacement appears warranted in pacemaker-dependent
patients. Indeed, of the nonfailed Fidelis leads removed
from service, 36% (n  19) were in 100%-paced patients.
lthough in our study 100% pacing was not associated with
ncreased mortality, 1 pacemaker-dependent patient pre-
ented with pre-syncope due to inability to pace and
equired an emergent intervention for ventricular asystole.
nother patient receiving CRT had evidence of failure to
ace on interrogation but did not have any clinical events
econdary to lead failure. These highlight the potential risk
n this subpopulation.
Fracture of the high-voltage element accounts for 10% of
idelis lead failures (16). Daily impedance measurements
creen for impedance conductor failure, with reported sen-
itivity of impedance changes ranging from 83% to 92.9%
21,22). In order to result in an unwarned fatal event, a
igh-voltage failure and a life-threatening arrhythmic event
ust occur within 24 h, or the failure must be underde-
ected by daily impedance monitoring.
nappropriate shocks. The most common adverse events
ssociated with Fidelis lead failure are inappropriate device
herapies. Inappropriate device therapies may result in death
11), diminished overall survival (23), pain, depression, and
iminished quality of life (24). Lead failure presenting as
nappropriate shock ranges from 21% (8) to 83% (7). In our
tudy, 38 of 85 (45%) of Fidelis failures presented with
nappropriate shocks. Downloadable algorithms that in-
rease the number of intervals to detect are associated with
79% relative reduction in the occurrence of inappropriate
hocks and therefore represent an important component of
reventing these events (20).
Multivariate Predictors of MortalityTable 3 Multivariate Predictors of Mortality
Hazard Ratio (95% CI) p Value
Lead type (Fidelis vs. Quattro) 1.056 (0.84–1.33) 0.6353
ICD indication (secondary vs. primary) 1.380 (1.08–1.76) 0.0097
Atrial lead 1.409 (1.10–1.81) 0.0077
Heart failure 1.611 (1.21–2.14) 0.001
Number of generator replacements 0.310 (0.24–0.41) 0.0001
Age (per 1-yr increase) 1.036 (1.026–1.05) 0.0001
History of peripheral arterial disease 1.529 (1.18–1.99) 0.0016
Ejection fraction (per 1% increase) 0.978 (0.968–0.99) 0.0001
Atrial fibrillation 1.609 (1.31–1.98) 0.0001
Chronic dialysis 3.298 (2.19–4.97) 0.0001
Chronic obstructive pulmonary disease 1.372 (1.08–1.75) 0.0108Abbreviations as in Tables 1 and 2.
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than that reported by the manufacturer: 93.8% to 95.4% at
48 months (25). The discrepancy highlights the complexity
of and resources necessary to identify failure events that
exceed the background component failure present in all
devices, and may also reflect differences in populations and
in follow-up methodologies.
Managing patients with Fidelis leads. Management of
patients with implanted Fidelis leads involves balancing the
risk of malfunction, the ability of surveillance to detect
malfunction before catastrophic clinical events, and the risk
of intervention. Current manufacturer recommendations for
managing patients with Fidelis leads entail continued clin-
ical follow-up with the addition of the Lead Integrity Alert
downloadable algorithm (16). Our data support this strategy
for most patients, in that mortality was not increased
utilizing a fairly conservative approach. This argues against
prophylactic removal of a normally functioning Fidelis lead
from service in a nonpacemaker-dependent patient.
However, management must be tailored to patient risk.
The Lead Integrity Alert algorithm is limited to patients
with Medtronic pulse generators, does not provide ad-
vanced warning in approximately 25% of patients, and is
limited in part by the inability of older patients to hear
alert tones (26). Clinical predictors of lead failure include
higher ejection fraction (27), age 50 years, and, possibly,
sports/physical activity (10). Additionally, the risk of lead
failure appears to continue to increase over time (6,14,15).
Thus, although an increased mortality was not seen in
100%-paced patients, the sample size may have limited
detection of risk in this subpopulation, and prophylactic
lead replacement in this population appears reasonable.
Other groups in whom prophylactic lead replacement (typ-
ically at the time of pulse generator battery depletion) may
be reasonable include young patients (under 50 years), those
with preserved ejection fraction, those who are quite active
physically, and those with spontaneous ventricular tachycar-
dia/fibrillation events (who are thus at increased risk for
recurrence). Whether advisory leads are abandoned or
extracted depends on patient characteristics and physician
and medical center skills and resources, and has been
reviewed elsewhere (28–30).
ICD versus arrhythmia management system. Historically
ICDs, were autonomously functioning implanted rhythm
management devices, with periodic modifications (program
changes) applied by caregivers. Our study highlights the fact
that ICDs are part of a complex ecosystem that begins at
implantation, and must include sophisticated follow-up
entailing automated, direct patient and Internet-enabled
alerts, practitioner visits, system modification with down-
loadable software, and revision when needed. Ongoing
surveillance by heart rhythm experts not only may detect
impending system malfunction, but may identify impending
clinical changes (e.g., incipient pulmonary edema or asymp-
tomatic atrial fibrillation) that warrant pharmacological or
other therapy independent of device function (31,32). Thisis supported by our finding that the predictors of death were
not device function but medical comorbidities, a finding
consistent with other studies (33).
Study limitations. Although data were collected prospec-
tively for ICD databases at each center and merged for the
purposes of this study, the analysis performed was retro-
spective and is therefore subject to all of the limitations of a
retrospective analysis. All participating centers are referral
centers, and therefore, our study population may not be
representative of an average practice population. Although
we did compare the Fidelis to a nonadvisory lead, we did not
compare it to leads from other manufacturers. Lastly, we
were unable to adjudicate the mechanism of death to
estimate the probability of death due to lead failure.
Conclusions
In a cohort managed with a relatively conservative approach
that predominantly entailed observation, adjusted survival is
similar between patients with Fidelis and Quattro ICD
leads.
Reprint requests and correspondence: Dr. Paul A. Friedman,
Division of Cardiovascular Disease, Mayo Clinic, 200 1st Street SW,
Rochester, Minnesota 55905. E-mail: Friedman.Paul@mayo.edu.
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